EMIT Imaging

EMIT Imaging is a private, early-revenue stage company founded in 2016 and based in Cambridge, Massachusetts. It has developed a proprietary preclinical imaging platform called Xerra™, which utilizes Cryo-Fluorescence Tomography (CFT) to bridge the resolution gap between cellular microscopy and whole-body imaging techniques like MRI and PET. The technology is positioned as a critical tool for advancing research in drug discovery, oncology, gene therapy, and neuroscience by providing definitive, quantitative 3D data on drug delivery and biological processes. The company operates on a hybrid business model, generating revenue from the sale of its instrumentation and by providing fee-for-service imaging to research organizations.

Cryo-Fluorescence Tomography (CFT) - a high-resolution, high-sensitivity 3D volumetric imaging technology for ex vivo whole animals and tissues, commercialized as the Xerra™ platform.

EMIT competes with large preclinical imaging companies like Bruker and PerkinElmer that offer in vivo optical, PET, SPECT, and CT systems. Its primary differentiation is the high resolution and sensitivity of its ex vivo CFT technology, which fills a gap between low-resolution whole-body imaging and high-resolution microscopy, though it requires tissue processing.